Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.

David M WaterhouseSacha RothschildChristophe DoomsBertrand MennecierFarastuk BozorgmehrMargarita MajemMichel H van den HeuvelHelena LinardouByoung Chul ChoRachel Roberts-ThomsonKentaro TanakaNormand BlaisGustavo SchvartsmanKarin Holmskov HansenIzabela ChmielewskaMartin D ForsterChristina GiannopoulouBjörn StollenwerkCynthia C ObiozorYang WangSilvia Novello

Published in: Lung cancer (Amsterdam, Netherlands) (2024)

Patients receiving sotorasib reported less severe symptoms than those receiving docetaxel. In addition to improving clinical efficacy outcomes, sotorasib maintained QOL versus docetaxel, suggesting sotorasib may be a more tolerable treatment option for patients with pretreated, KRAS G12C-mutated advanced NSCLC.

Keyphrases

patient reported outcomes
small cell lung cancer
wild type
locally advanced
advanced non small cell lung cancer
squamous cell carcinoma
metabolic syndrome
physical activity
combination therapy
depressive symptoms
replacement therapy
glycemic control